Gamma camera probe developer Neoprobe has received U.S. Food and Drug Administration clearance to launch a phase III multicenter clinical study of its Lymphoseek radiopharmaceutical agent.
The Dublin, OH-based firm plans to enroll approximately 200 patients at up to 25 cancer treatment centers in the U.S. and Europe. Neoprobe said that it is also preparing for a second phase III trial to involve fewer than 200 patients with head and neck squamous cell carcinoma. That trial is expected to begin around midyear, according to the firm.
In other news, the company has received $3 million in funding from investment fund Platinum-Montaur Life Sciences of New York City, Neoprobe said. The funds will be used to begin the phase III clinical trials of Lymphoseek.
Related Reading
Neoprobe announces phase II Lymphoseek results, March 13, 2008
Neoprobe nets financing, December 27, 2007
Neoprobe extends agreement with Ethicon, December 20, 2007
Neoprobe, Cardinal Health ink distribution deal, November 28, 2007
Neoprobe cuts loss on higher sales, October 31, 2007
Copyright © 2008 AuntMinnie.com
